Source: BUSINESS WIRE

Press Release: Altravax : Research and Markets: Dengue Therapeutics Pipeline Review, H2 2015 - 37 Companies & 80 Drug Profiles

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rwjdb6/dengue_pipeline) has announced the addition of the "Dengue - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, an

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Michael Chambers's photo - Interim-CEO of Altravax

Interim-CEO

Michael Chambers

CEO Approval Rating

70/100

Read more